The Gilead Genese Prize will be instrumental for the construction of the capture MNPs and validation of molecular assays on patient samples. This endeavor is only possible due to the long-lasting collaboration between IHMT-NOVA TB Group lead by Miguel Viveiros and João Piedade for HIV and the Nanomedicine Group lead by Pedro V. Baptista at UCIBIO, Dept of Life Sciences, FCT-NOVA.